The FDA’s approval is based on data from a late-stage trial, which showed that 36.2 per cent of patients treated with Lymphir showed partial or complete response to the treatment while reducing skin disease in 84% of patients in the study.
News
US FDA approves Citius’ blood cancer therapy
August 9, 2024
The FDA’s approval is based on data from a late-stage trial, which showed that 36.2 per cent of patients treated with Lymphir showed partial or complete response to the treatment while reducing skin disease in 84% of patients in the study.